Aromazin v ad\"yuvantnoy terapii raka molochnoy zhelezy


Рак молочной железы (РМЖ) остается одной из наиболее серьезных проблем здравоохранения как в России, так и во всем мире. Ежегодно выявляется более 1 млн 200 тыс. новых случаев РМЖ, что составляет 10% от общего числа онкологических заболеваний.Несмотря на продолжающийся рост заболеваемости РМЖ, показатели смертности от него в ряде стран прогрессивно снижаются: за период с 1990 по 2002 г. в Западной Европе и США зарегистрировано сокращение смертности на 17 и 24% соответственно. Этот факт обусловлен не только совершенствованием методов ранней диагностики и широким внедрением скрининговых программ, но и проведением современной адекватной адъювантной химиотерапии (ХТ) и гормонотерапии. Применение адъювантного системного лечения после радикального оперативного вмешательства достоверно снижает риск рецидива и смерти от прогрессирования

Full Text

Restricted Access

About the authors

E V Artamonova


  1. Семиглазов В.Ф., Семиглазов В.В., Нургазиев К.Ш. Обоснование стандартов лечения рака молочной железы. М., 2007; с. 202–3.
  2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; V365: 1687–717.
  3. EBCTCG New advances in the treatment of breast cancer. San Antonio, 2007.
  4. Goldhirsch A, Ingle J.N., Gelber R.D. et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009; 20: 1319–29.
  5. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node - negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684–90.
  6. Zilembo N, Bajetta E, Martinetti A et al. Markers of bone turnover in metastatic breast cancer (MBC) patients having progressed on tamoxifen: short term effect of further treatment with either exemestane (EXE) or megestrol acetate (MA). Eur J Cancer 2001; 37(Suppl. 6): S193.
  7. Gossa P.E., Qia S, Josseb R.G. et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004; 34 (3): 384–92.
  8. Lohrisch C, Paridaens R, Dirix L et al. No adverse impact on serum lipids of the irreversible aromatase inactivator AromasinR (Exemestane [E]) in 1st line treatment of metastatic breast cancer (MBC): companion study to a European Organization for the Research and Treatment of Cancer (Breast Group) Trial with Pharmacias' Upjohn. Proc Am Soc Clin Oncol 2001; 20 (43a): Abstr. 167.
  9. Kaufmann M, Bajetta E, Dirix L.Y. et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double - blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18: 1399–411.
  10. Paridaens R.J., Dirix L.Y., Beex L.V. et al. Phase III Study Comparing Exemestane With Tamoxifen As First - Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008; 26 (30): 4883–90.
  11. Coombes R.S., Kilburn L.S., Snowdon C.F. et al. Survival and safety of exemestane versus tamoxifen therapy after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007; 369: 559–70.
  12. Coombes R.S., Hall E, Gibson L.J. et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92.
  13. Bliss J.M., Kilburn L.S., Coleman R.E. et al. Disease related outcome with long term follow - up: an updated analysis of the Intergroup Exemestane Study (IES). Cancer Res 2009; 69 (Suppl.): 487s, abstr. 12.
  14. Mamounas E, Jeong J-H, Wickerham L et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent - to - treat analysis of NSABP B-33. Breast Cancer Res Treat 2006; 100 (Suppl. 1): S22 (Abstr 49).
  15. Saphner T, Tormey D.C., Grayet R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738–46.
  16. Ellis M.J., Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor - positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808–16.
  17. Dowsett M, Allred C, Knox J et al. Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clin Oncol 2008; 26 (7): 1059–65.
  18. Goldhirsch A., Wood W.S., Gelber R.D. et al. Progress and promise: high - lights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133–44.
  19. Van de Velde C, Seynaeve C, Hasenburg A et al. Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. EJC 2009; 7, 3 (Suppl.): p 1, abstr. 2BA.
  20. Jones S.E., Seynaeve C, Hasenburg A et al. Results of the first analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. SABS 2008.
  21. Geisler J, Haynes B, Anker G et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in randomized, cross - over study. J Clin Oncol 2002; 20: 751–7.
  22. Geisler J, King N B, Anker G et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor in postmenopausal breast cancer patients. Clin Camcer Res 1998; 4: 2089–93.



Abstract - 11



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies